Nabumetone

Sold as Relitone, Relisan s, Relisan

C₁₅H₁₆O₂228.29 g/mol

4-(6-Methoxynaphthalen-2-yl)butan-2-one

Drag to rotate. Structure from PubChem CID 4409.

Loading Wikipedia summary

Registration

Applicants: 2
Registrations: 3

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Pharmacare limited û woodmeadCancelled	Relitone	Not stated	270105	Not determined	None
Viatris South Africa (Pty) Ltd	Relisan s, Relisan	Not stated	290272, Z0361	Not determined	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Relitone* EACH TABLET CONTAINS NABUMETONE 500 mg	Not listed	27010527/3.1/0105	Cancelled	Not determined	None
Relisan s 5 ML NABUMETONE 500 MG	Not listed	29027229/3.1/0272	Registered	Not determined	None
Relisan EACH TABLET CONTAINS NABUMETONE 500 mg	Not listed	Z0361Z/3.1/361	Registered	Not determined	None

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S3: Nabumetone
- except when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)
Consolidated Schedules 06 July 2026, lines 3971 to 3972
S2: Nabumetone
- when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S3)
Consolidated Schedules 06 July 2026, lines 2363 to 2364

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading PubMed articles

Background